Results 351 to 360 of about 427,029 (392)
Some of the next articles are maybe not open access.
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
New England Journal of MedicineBACKGROUND Patients with newly diagnosed chronic myeloid leukemia (CML) need long-term therapy with high efficacy and safety. Asciminib, a BCR::ABL1 inhibitor specifically targeting the ABL myristoyl pocket, may offer better efficacy and safety and fewer
A. Hochhaus +21 more
semanticscholar +1 more source
Current Opinion in Hematology, 1997
The molecular origin of the BCR-ABL chimeric gene is now reasonably well defined; a new breakpoint cluster region in the BCR gene, designated mu-bcr, has recently been identified. p210BCR-ABL binds with or phosphorylates a wide variety of intracellular proteins but the mechanism by which it exerts its oncogenic potential is not yet known.
openaire +2 more sources
The molecular origin of the BCR-ABL chimeric gene is now reasonably well defined; a new breakpoint cluster region in the BCR gene, designated mu-bcr, has recently been identified. p210BCR-ABL binds with or phosphorylates a wide variety of intracellular proteins but the mechanism by which it exerts its oncogenic potential is not yet known.
openaire +2 more sources
Revue medicale suisse, 2005
Chronic myeloid leukemia is one of the commonest hematological malignancies seen in clinical practice. It is the result of abnormal and excess cell proliferation due to de-regulated bcr-abl tyrosine kinase activity as a result of Philadelphia chromosome. The present article discusses the various options available to treat the disorder.
A, Gratwohl, G, Favre
openaire +3 more sources
Chronic myeloid leukemia is one of the commonest hematological malignancies seen in clinical practice. It is the result of abnormal and excess cell proliferation due to de-regulated bcr-abl tyrosine kinase activity as a result of Philadelphia chromosome. The present article discusses the various options available to treat the disorder.
A, Gratwohl, G, Favre
openaire +3 more sources
Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia
Leukemia, 2022J. Senapati +3 more
semanticscholar +1 more source
2007
In attempting to apply evidence-based medicine in the treatment of chronic myeloid leukemia (CML), it must be acknowledged that a randomized study comparing imatinib mesylate therapy and allogeneic stem cell transplantation (SCT) has not been conducted.
openaire +1 more source
In attempting to apply evidence-based medicine in the treatment of chronic myeloid leukemia (CML), it must be acknowledged that a randomized study comparing imatinib mesylate therapy and allogeneic stem cell transplantation (SCT) has not been conducted.
openaire +1 more source
Onconephrology: The intersections between the kidney and cancer
Ca-A Cancer Journal for Clinicians, 2021, Kenar D Jhaveri, Mark A Perazella
exaly
Simultaneous chronic myeloid leukemia and chronic lymphocytic leukemia
Blood, 2011Edwarda M, Buda-Okreglak +1 more
openaire +2 more sources